我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
39
6 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1956
进行中(未招募)
3
7.7%
已完成
20
51.3%
尚未招募
招募中
7
17.9%
终止
2
5.1%
Unknown
撤回
暂无批准数据
- A first-of-its-kind study by OHSU and National University of Natural Medicine found that low-income adults with major depressive disorder experienced significant depression reduction following group psilocybin therapy sessions. - Nineteen participants completed two psilocybin administration sessions and showed sustained improvements three months later, with average satisfaction ratings of 4.8 out of 5. - The group therapy model cost $11,000 total for all participants compared to $4,500 per individual session, potentially making the breakthrough therapy more accessible despite current insurance barriers. - Researchers reported no serious adverse events during the study, with only minor temporary side effects like nausea and headaches observed in some participants.